Streetbeat News

Partnerships

HCP

Google Cloud and HashiCorp, Inc. (NASDAQ: HCP) have announced an expanded partnership to integrate generative AI into HashiCorp's products using Google Cloud's Vertex AI. This collaboration aims to enhance automation workflows for developers and accelerate cloud transformation. HashiCorp will also add support for Google Cloud's Duet AI to assist with Terraform configurations. The partnership, which includes clients like Deutsche Bank and Vodafone, will develop AI models tailored to HashiCorp's customer use cases and strengthen Terraform's AI compatibility.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 3:29 pm

CVX

Venezuela's Deputy Oil Minister announced that PDVSA's unit CVP and U.S. Chevron (CVX) have sought a 15-year extension for two joint ventures from the Venezuelan government, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 3:18 pm

EPAM

EPAM Systems, Inc. has launched its AI-powered DIAL Open Source Platform, designed to facilitate the development of applications using large language models (LLMs). The platform is adaptable, model-agnostic, and supports a wide range of applications across industries. It is already used in over 500 use cases and is available under the Apache 2.0 license, promoting open source collaboration. EPAM's DIAL platform is containerized, Kubernetes-ready, and compatible with major public cloud providers. The company also highlighted StatGPT, a tool developed on the DIAL platform to automate SDMX queries using LLMs.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 3:04 pm

GOOGL

Google has introduced Gemini Pro, an enhanced generative AI feature for cloud customers, targeting businesses and app developers. It is now integrated into Google AI Studio and Vertex AI Developer tools. This move is part of Google's efforts to compete with Microsoft and OpenAI in the cloud AI space.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 3:04 pm

LLY

Ro, a direct-to-patient healthcare company, has expanded its Body Program with the launch of Zepbound (tirzepatide), an FDA-approved weight loss treatment from Eli Lilly and Company. Zepbound has shown significant results in clinical trials, helping people lose an average of 48 pounds over 72 weeks. Ro's Body Program offers a comprehensive telehealth weight loss solution, integrating various medications, insurance coverage verification, side effect tracking, and AI learning models. The program also integrates with Apple Health for data sharing.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 2:54 pm

AGS

AGS has partnered with Three Rivers Resort to create an AGS-exclusive table games floor. The installation includes 12 of AGS' systems, premium felt games such as Jackpot Hold'Em, 3 Card, Dealer Open Pai Gow, and blackjack side bets like Lucky Lucky and Buster Blackjack. Additionally, AGS' single-deck shuffler, Pax S, is making its Oregon casino debut at each card table.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 2:27 pm

CRKN

Crown Electrokinetics has announced a strategic partnership with Blue Edge Infrastructure, where Crown Fiber Optics' Division has secured primary contractor status. This partnership extends Crown's market influence from Arizona to a nationwide scale.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 2:24 pm

NVEI

Nuvei Corporation (NASDAQ:NVEI) has partnered with Familiprix, a major Canadian pharmacy chain, to launch an eCommerce app allowing Familiprix customers to make online purchases for the first time. Nuvei's payment platform will provide authorization, settlement, and user management solutions to Familiprix, aiming to optimize payment operations and enhance customer experience with secure online transactions. The partnership is expected to extend Familiprix's market reach and improve service offerings to its customers across Quebec and New Brunswick.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 2:07 pm

EDIT

VRTX

Editas Medicine has entered into a license agreement with Vertex Pharmaceuticals, granting Vertex a non-exclusive license to use Editas' Cas9 gene editing technology for CASGEVY™ (exagamglogene autotemcel). This agreement extends Editas Medicine's cash runway into 2026.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 2:06 pm

AFRM

Affirm (NASDAQ: AFRM) has partnered with Zenni Optical to offer a flexible payment option for customers purchasing eyewear. Eligible Zenni customers can now split purchases over $75 into monthly payments without hidden or late fees. The partnership aims to enhance the customer experience and increase purchasing power responsibly. Affirm's payment option has already shown an increase in average spending on eyewear during Black Friday, indicating strong consumer demand for such flexible payment solutions.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 2:02 pm